PARP1 and Huntington disease: In the present study, we utilized a PARP-1 inhibitor that is already in use for other diseases to possibly accelerate the process towards offering a viable pharmaceutical compound to HD patients, and we describe how Olaparib was beneficial in the primary outcome measures.